Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and dicyclomine, an anticholinergic antispasmodic.
## Primary Indications
* Management of abdominal pain associated with smooth muscle spasms, particularly in conditions like irritable bowel syndrome, diverticulitis, and colicky pain.
* Relief of mild to moderate pain, especially when associated with inflammatory conditions and smooth muscle spasm.
## Adult Dosing
* **Meftal spas:** Typically, 1 tablet orally every 8 hours as needed. Maximum daily dose is usually 4 tablets. Doses should be taken with food to minimize gastrointestinal upset.
* **Mefenamic acid alone:** 500 mg orally every 6 hours.
* **Dicyclomine alone:** 10-20 mg orally 3 to 4 times daily.
## Pediatric Dosing
Dosing for Meftal spas in pediatric patients is not well-established. Mefenamic acid: 6.5 mg/kg orally every 6 hours, maximum 500 mg/dose. Dicyclomine: Dosing is highly variable and should be individualized based on age and weight, with caution due to potential side effects. Consult pediatric-specific resources.
## Dose Adjustments
* **Renal Impairment:** Caution and potential dose reduction for mefenamic acid component may be warranted in severe renal impairment.
* **Hepatic Impairment:** Caution and potential dose reduction for mefenamic acid component may be warranted in severe hepatic impairment.
* **Elderly:** Increased risk of adverse effects with mefenamic acid (GI bleeding, renal dysfunction) and dicyclomine (confusion, urinary retention). Lower starting doses may be considered.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or other NSAIDs or anticholinergics.
* Patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Inflammatory bowel disease (active or chronic).
* Obstructive uropathy.
* Glaucoma (especially narrow-angle).
* Myasthenia gravis.
* Gastrointestinal obstruction or perforation.
* Uncontrolled heart failure.
* Severe renal or hepatic impairment.
* Third trimester of pregnancy.
## Adverse Effects
* **Mefenamic Acid:** Gastrointestinal (nausea, vomiting, diarrhea, dyspepsia, abdominal pain, GI bleeding, ulceration), renal (acute kidney injury, interstitial nephritis), hepatic (elevated liver enzymes), cardiovascular (increased risk of thrombotic events), hematologic (anemia).
* **Dicyclomine:** Anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation, drowsiness, dizziness, confusion), tachycardia.
## Key Drug Interactions
* **Mefenamic Acid:**
* Anticoagulants (e.g., warfarin): Increased risk of bleeding.
* Corticosteroids: Increased risk of GI ulceration/bleeding.
* ACE inhibitors, ARBs, Diuretics: May reduce antihypertensive effect and increase risk of renal dysfunction.
* Lithium: Increased lithium levels.
* Methotrexate: Increased methotrexate toxicity.
* **Dicyclomine:**
* Other anticholinergics (e.g., tricyclic antidepressants, antihistamines): Potentiated anticholinergic effects.
* Amantadine: Potentiated anticholinergic effects.
* MAOIs: May prolong and intensify anticholinergic effects.
## Monitoring
* **For Mefenamic Acid:** Monitor for signs of GI bleeding (melena, hematemesis), renal function (BUN, creatinine), liver function tests, blood pressure, and signs of cardiovascular events.
* **For Dicyclomine:** Monitor for efficacy in reducing spasms and for anticholinergic side effects.
## Clinical Pearls
* Meftal spas should be used for the shortest duration necessary to control symptoms.
* Avoid concurrent use with other NSAIDs to minimize risk of adverse effects.
* Patients with pre-existing renal or hepatic disease should be closely monitored.
* Elderly patients are at higher risk for adverse events.
* The combination addresses both pain and spasm components of abdominal discomfort.
***
*This information is intended for healthcare professionals. It is crucial to consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient-specific appropriateness.*
